Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2024

Collaboration Agreement [Abstract]

Summary of Activity and Reimbursement Amounts Related to Collaboration Agreement

The following table summarizes the Company’s proportionate share of the activity under the Biogen Collaboration Agreement accounted for under Topic 808, including activities associated with the sale of ZURZUVAE in the U.S., as well as costs during the periods related to the development of SAGE-217 products and SAGE-324 products, as reflected in our condensed consolidated statement of operations and comprehensive loss:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
	(in thousands)				(in thousands)
Collaboration revenue - related party	$	11,028	$	—	$	24,661	$	—
Cost of revenues		1,553		—		4,048		—
Research and development expenses		6,493		34,855		18,467		84,705
Selling, general and administrative expenses		14,792		25,908		40,847		73,626

The revenue, cost and expense categories in the table below reflect the following reimbursement amounts to (from) Biogen to account for the sharing of economics under the Biogen Collaboration Agreement:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
	(in thousands)						(in thousands)
Collaboration revenue - related party	$	(11,028	)	$	—		$	(24,661	)	$	—
Cost of revenues		(905	)		—			(2,033	)		—
Research and development expenses		(5,423	)		(28,204	)		(14,405	)		(67,903	)
Selling, general and administrative expenses		2,419			5,835			5,744			16,345